Intepirdine

Intepirdine
Systematic (IUPAC) name
3-Phenylsulfonyl-8-(piperazin-1-yl)quinoline
Clinical data
Routes of
administration
Oral
Legal status
Legal status
  • Investigational
Identifiers
CAS Number 607742-69-8 YesY
ATC code none
PubChem CID 11256720
ChemSpider 9431746 N
UNII 2IOB2M82HY YesY
ChEMBL CHEMBL1083390 N
Synonyms SB-742457, RVT-101
Chemical data
Formula C19H19N3O2S
Molar mass 353.44 g/mol
 NYesY (what is this?)  (verify)

Intepirdine (INN; developmental codes SB-742457, RVT-101[1]) is a selective 5-HT6 receptor antagonist with potential cognition, memory, and learning-enhancing effects.[2][3][4][5] It was under development by GlaxoSmithKline for the treatment of Alzheimer's disease and demonstrated some preliminary efficacy in phase II clinical trials;[4][5][6] however, GSK chose not to continue development and sold the rights to Axovant Sciences in December 2014.[7][8]

References

  1. "RVT-101". Axovant.
  2. Upton N, Chuang TT, Hunter AJ, Virley DJ (July 2008). "5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease". Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics 5 (3): 458–69. doi:10.1016/j.nurt.2008.05.008. PMID 18625457.
  3. Idris N, Neill J, Grayson B, et al. (January 2010). "Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms". Psychopharmacology 208 (1): 23–36. doi:10.1007/s00213-009-1702-5. PMID 19851757.
  4. 1 2 Maher-Edwards G, Zvartau-Hind M, Hunter AJ, et al. (December 2009). "Double-Blind, Controlled Phase II Study of a 5-HT6 Receptor Antagonist, SB-742457, in Alzheimer's Disease". Current Alzheimer Research 7 (5): 374–85. PMID 20043816.
  5. 1 2 Rossé G, Schaffhauser H (February 2010). "5-HT(6) Receptor Antagonists as Potential Therapeutics for Cognitive Impairment". Current Topics in Medicinal Chemistry 10 (2): 207–21. doi:10.2174/156802610790411036. PMID 20166958.
  6. "Search of: SB-742457 - List Results - ClinicalTrials.gov".
  7. "Axovant Acquires SB742457 from GlaxoSmithKline" (Press release). Axovant. December 23, 2014.
  8. House, Douglas W. (June 5, 2015). "Axovant Sciences on deck for IPO". Seeking Alpha.


This article is issued from Wikipedia - version of the Tuesday, May 03, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.